Envoy Medical, Inc.
Envoy Medical, Inc. develops and commercializes implantable hearing devices, with current revenue coming primarily from the Esteem FI-AMEI fully implanted active middle ear implant and related replacement components. The company is also advancing its Acclaim CI cochlear implant program, which is still in clinical development and targeted for future FDA approval and commercialization.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2021–2025
Liiketoiminta
Osuus liikevaihdostaSales of the Esteem FI-AMEI implant system and related replacement components used in implanted patients.
Battery/sound processor replacements and other recurring post-implant components for existing patients.
R&D work for the Acclaim CI cochlear implant and continued support for the Esteem platform.
Asiakkaat
Envoy Medical sells to patients and the clinical providers who implant and manage its hearing devices, with reimbursement and surgical adoption being central to demand. Current revenue is driven by a very small installed base of Esteem FI-AMEI patients, while future growth depends on successful clinical trial execution and eventual commercialization of Acclaim CI.
Patients who receive the Esteem FI-AMEI device and later buy replacement components or services.
ENT surgeons, hospitals, and clinical centers that implant and support the devices.
Insurers and coverage authorities that determine whether patients can access the devices economically.
Potential Acclaim CI customers if the product receives FDA approval and reaches commercialization.
Strategia
Envoy Medical is focused on extending the life of its current implant franchise while advancing Acclaim CI through staged clinical trials and toward PMA submission. A major strategic priority is securing favorable reimbursement and regulatory outcomes, since both are necessary to expand adoption beyond the small current installed base.
The product is the main future growth driver and requires successful trial execution before PMA filing.
Regulatory clearance is required before Acclaim CI can generate meaningful revenue.
Coverage changes could materially expand patient access and implant volumes.
The company is loss-making and depends on external financing to support trials and operations.
Maantiede
The company is headquartered in the United States and its current commercial activity is centered on the U.S. market. Its near-term operating footprint is also U.S.-based because clinical development, FDA interactions, and reimbursement efforts are the main drivers of the business.
Riskit
Envoy Medical faces substantial execution risk because it is still funding clinical development and has a limited commercial base. Its business is also exposed to regulatory timing, reimbursement uncertainty, and financing needs, all of which can materially affect the pace of product adoption and the company’s ability to continue operations.
Acclaim CI must complete staged trials and PMA review before commercialization, so any delay pushes out revenue and increases cash burn.
Kohdistuu: Acclaim CI program
The company explicitly relies on positive reimbursement changes to expand implant volumes and patient access.
Kohdistuu: Esteem FI-AMEI and future Acclaim CI adoption
The company has incurred significant operating losses and has funded operations primarily through equity and debt financing.
Kohdistuu: Corporate operations and clinical trials
Current revenue comes substantially all from a single product family and a very small number of implant events.
Kohdistuu: Esteem FI-AMEI implants and replacements
The company carries excess/obsolete inventory reserves and write-offs, which can rise if demand remains low or product mix changes.
Kohdistuu: Cost of goods sold and gross margin
Kirjanpito
Harkinnanvaraiset erätSales are recorded when the company is notified the product has been implanted or used, so timing of surgery drives reported revenue.
Vaikutus: Can shift revenue between quarters and make trends lumpy
COGS includes excess and obsolete inventory reserves, which can rise if demand remains limited.
Vaikutus: Affects gross margin and operating loss
The company uses fair value estimates for certain financing-related instruments and other liabilities.
Vaikutus: Can create non-cash gains or losses
Equity awards are expensed over the service period using valuation models.
Vaikutus: Raises operating expenses without immediate cash outflow
Debt and insurance financing loans affect other expense and net loss.
Vaikutus: Can materially change reported bottom-line results
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
ENvue Medical, Inc.
FEED · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Enovis CORP
ENOV · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Enovis is a U.S.-based medical technology company focused on orthopedic and musculoskeletal care.
Envista Holdings Corp
NVST · Dental Equipment & Supplies
Envista Holdings Corp is a U.S.-based dental products company built around more than 30 brands, including Nobel Biocare, Ormco, DEXIS, and Kerr.
Enovix Corp
ENVX · Miscellaneous Electrical Machinery, Equipment & Supplies
Enovix Corp designs and manufactures advanced lithium-ion batteries and battery packs built around its silicon-anode architecture.
enVVeno Medical Corp
NVNO · Surgical & Medical Instruments & Apparatus
enVVeno Medical Corp is a U.S.-based medical device company focused on developing bioprosthetic venous valve technologies for severe chronic venous insufficiency.
Encision Inc
ECIA · Surgical & Medical Instruments & Apparatus
Päivitetty: 24.9.2026